MX2017000862A - Formulacion de factor viii. - Google Patents

Formulacion de factor viii.

Info

Publication number
MX2017000862A
MX2017000862A MX2017000862A MX2017000862A MX2017000862A MX 2017000862 A MX2017000862 A MX 2017000862A MX 2017000862 A MX2017000862 A MX 2017000862A MX 2017000862 A MX2017000862 A MX 2017000862A MX 2017000862 A MX2017000862 A MX 2017000862A
Authority
MX
Mexico
Prior art keywords
formulation viii
factor formulation
factor
viii
relates
Prior art date
Application number
MX2017000862A
Other languages
English (en)
Other versions
MX379126B (es
Inventor
Metzner Hubert
Liebing Uwe
Bodenbender Christina
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of MX2017000862A publication Critical patent/MX2017000862A/es
Publication of MX379126B publication Critical patent/MX379126B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a composiciones de Factor VIII y su uso.
MX2017000862A 2014-08-04 2015-07-24 Formulación de factor viii. MX379126B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179732 2014-08-04
PCT/EP2015/066999 WO2016020210A1 (en) 2014-08-04 2015-07-24 Csl behring gmbh

Publications (2)

Publication Number Publication Date
MX2017000862A true MX2017000862A (es) 2017-05-01
MX379126B MX379126B (es) 2025-03-10

Family

ID=51298563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000862A MX379126B (es) 2014-08-04 2015-07-24 Formulación de factor viii.

Country Status (16)

Country Link
US (1) US10238718B2 (es)
EP (1) EP3177317B1 (es)
JP (1) JP6516829B2 (es)
KR (1) KR102192494B1 (es)
CN (1) CN106687126B (es)
AU (1) AU2015299224B2 (es)
BR (1) BR112017002090B1 (es)
DK (1) DK3177317T3 (es)
ES (1) ES2788870T3 (es)
IL (1) IL250343B (es)
MX (1) MX379126B (es)
NZ (1) NZ729629A (es)
PL (1) PL3177317T3 (es)
RU (1) RU2689338C2 (es)
SG (2) SG11201700550YA (es)
WO (1) WO2016020210A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018101358A1 (ja) * 2016-11-29 2018-06-07 Ｓｐｉｂｅｒ株式会社 タンパク質組成物、その製造方法及び熱安定性向上方法
WO2018132874A1 (en) * 2017-01-19 2018-07-26 Csl Limited Method of preventing an immune response with alpha- 1 anti-trypsin
CA3082043A1 (en) * 2017-11-07 2019-05-16 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技（上海）有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用
CN121926888A (zh) * 2019-06-28 2026-04-28 北京基科晟斯医药科技有限公司 重组凝血因子viii制剂
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
EP0410207B1 (en) 1989-07-24 1997-01-22 Bayer Corporation Stabilization of highly purified proteins
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
DE69333928T2 (de) 1992-04-30 2006-08-17 Probitas Pharma Inc., Los Angeles Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
SE9501189D0 (sv) 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
KR20150138427A (ko) * 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
US7523304B2 (en) * 2005-11-22 2009-04-21 Ntt Docomo, Inc. Generation of set coverings with free riders, and generation of ordered sets of meeting points, in systems which include, but are not limited to, systems for broadcast encryption and systems for certificate revocation
RS52459B (sr) 2006-02-07 2013-02-28 Shire Human Genetic Therapies Inc. Stabilizovane kompozicije glukocerebrozidaze
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
MX2009007145A (es) 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
WO2009007451A1 (en) 2007-07-11 2009-01-15 Novo Nordisk A/S Purification of factor viii using a mixed-mode or multimodal resin
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
CN107050437A (zh) * 2008-09-03 2017-08-18 奥克塔法马股份有限公司 重组制备的因子viii的新型保护组合物
JP5785872B2 (ja) 2008-10-17 2015-09-30 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 低度の水溶性ポリマーを含む改変血液因子
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
JP2012518029A (ja) 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
US20120093840A1 (en) 2009-04-06 2012-04-19 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US9493543B2 (en) 2010-02-16 2016-11-15 Novo Nordisk A/S Factor VIII fusion protein
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
WO2011101277A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Conjugated proteins
US8859731B2 (en) 2010-04-21 2014-10-14 Novo Nordisk A/S Selective modification of proteins
US20130183280A1 (en) 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
EA032336B1 (ru) 2010-09-17 2019-05-31 Баксалта Инкорпорейтид Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
CA2850579A1 (en) 2011-10-18 2013-04-25 Carsten Horn Method for improving the stability of purified factor viii after reconstitution
CN102580062B (zh) * 2012-03-09 2017-03-08 中国医学科学院输血研究所 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂
WO2013083858A1 (en) * 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
CN104519912A (zh) * 2012-08-13 2015-04-15 诺和诺德A/S（股份有限公司） 液体因子viii制剂

Also Published As

Publication number Publication date
CN106687126A (zh) 2017-05-17
RU2017106159A (ru) 2018-09-06
SG10201900598TA (en) 2019-02-27
WO2016020210A8 (en) 2016-04-28
BR112017002090A2 (pt) 2018-01-30
JP2017528440A (ja) 2017-09-28
KR20170040327A (ko) 2017-04-12
AU2015299224B2 (en) 2019-06-20
CN106687126B (zh) 2020-07-28
IL250343A0 (en) 2017-03-30
RU2689338C2 (ru) 2019-05-27
US10238718B2 (en) 2019-03-26
WO2016020210A1 (en) 2016-02-11
NZ729629A (en) 2021-12-24
JP6516829B2 (ja) 2019-05-22
RU2017106159A3 (es) 2018-11-28
DK3177317T3 (en) 2020-06-15
US20170252412A1 (en) 2017-09-07
EP3177317B1 (en) 2020-03-18
PL3177317T3 (pl) 2020-07-27
ES2788870T3 (es) 2020-10-23
AU2015299224A1 (en) 2017-03-23
SG11201700550YA (en) 2017-02-27
CA2956412A1 (en) 2016-02-11
KR102192494B1 (ko) 2020-12-18
BR112017002090B1 (pt) 2021-06-01
MX379126B (es) 2025-03-10
EP3177317A1 (en) 2017-06-14
IL250343B (en) 2020-10-29

Similar Documents

Publication Publication Date Title
IL268697A (en) Formulations
EP3722358A4 (en) COMPOSITION
DK3688162T3 (da) Formuleringer
EP3534968A4 (en) ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS
DK3697376T3 (da) Sammensætning
DK3359172T3 (da) Sammensætninger omfattende bakteriestammer
MA46458A (fr) Compositions debacillus thuringiensis
UY36499A (es) Uso de picolinamidas como fungicidas
DK3215173T3 (da) Glycopeptidsammensætninger
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
PT3393485T (pt) Composições probióticas e uso das mesmas
DK3600363T3 (da) Sammensætninger omfattende bakteriestammer
BR112017002090A2 (pt) formulação de fator viii
EP3554470A4 (en) COSMETIC COMPOSITIONS
MA45090A (fr) Compositions anticancéreuses
IL251859A0 (en) Methotrexate formulation
DK4234656T3 (da) Sammensætninger
EP3589716A4 (en) ADHESION IMPROVEMENT COMPOSITIONS
MX388186B (es) Granos de gluten reducido y composiciones de los mismos.
DK3638271T3 (da) Sammensætninger omfattende bakteriestammer
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
IL264445A (en) Compounds and compositions and uses thereof
HUE063178T2 (hu) Kopanlizib formulációi
DK3528791T3 (da) Dispergible sammensætninger
IL272167A (en) Hemopexin formulations